Status:
COMPLETED
An Investigator-initiated, Explorative Trial Evaluating the Effect of SAT-008 in Healthy Adults
Lead Sponsor:
Seoul National University Bundang Hospital
Collaborating Sponsors:
Korea University Guro Hospital
S-Alpha Therapeutics, Inc.
Conditions:
Allergy and Immunology
Eligibility:
All Genders
19-50 years
Phase:
NA
Brief Summary
The purpose of this exploratory study is to evaluate the efficacy, safety, and feasibility of a novel digital device called SAT-008 in healthy adults.
Detailed Description
This clinical study was designed as a single institution, open, controlled, and investigator-led clinical trial to evaluate the efficacy, safety, and feasibility of a novel digital device called SAT-0...
Eligibility Criteria
Inclusion
- Healthy adults aged 19 to 50 years
- Received influenza vaccination the previous year
- Scheduled to receive the influenza vaccine
- Voluntarily agrees with a consent form
Exclusion
- Current infectious disease
- History of autoimmune diseases
- Current immunological compromised diseases.
Key Trial Info
Start Date :
October 8 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 25 2021
Estimated Enrollment :
42 Patients enrolled
Trial Details
Trial ID
NCT04916145
Start Date
October 8 2020
End Date
January 25 2021
Last Update
June 7 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Seoul National University Bundang Hospital
Seongnam-si, Gyeonggi-do, South Korea, 13620